What Is Norethisterone Acetate and How Does It Work?

Norethisterone acetate is a synthetic progestogen that has been prescribed for decades to manage heavy periods, endometriosis, and menopausal symptoms, among other conditions. It belongs to a family of hormones derived from testosterone rather than progesterone, which gives it a pharmacological profile quite different from what many people expect of a “progestogen.” That testosterone-related ancestry shapes everything from how it handles period pain to why it sometimes causes acne, and it means the drug’s benefits and trade-offs are not always interchangeable with those of other progestins.

What Norethisterone Acetate Actually Is

Norethisterone acetate (often abbreviated NETA) is a prodrug. Once you swallow a tablet, your body strips off the acetate group and converts it into norethisterone (NET), which is the active compound. NET sits in the estrane subgroup of 19-nortestosterone derivatives, a chemical class that also includes older progestins like ethynodiol diacetate.¹ In practical terms, that lineage means norethisterone doesn’t just activate progesterone receptors. It also interacts with androgen receptors, estrogen receptors, and to a minor degree glucocorticoid receptors, each of which contributes a different slice of its clinical effects.

One feature that sets NETA apart from many other progestins is that a small fraction of it is converted into ethinyl estradiol, the same synthetic estrogen found in most combined birth control pills. In postmenopausal women, roughly 0.7% of a dose is transformed this way, which works out to about 6 micrograms of ethinyl estradiol per milligram of NETA taken by mouth.² That sounds tiny, but it is enough to contribute a measurable estrogenic effect, particularly at higher doses. It is one reason NETA has historically been considered protective against bone loss in menopause even before estradiol is added to the regimen.

Androgenic Activity and Why It Matters

Many progestins are loosely described as having “some androgenic activity,” but the laboratory data on NETA are more striking than that casual framing suggests. In receptor-binding studies, both NETA and medroxyprogesterone acetate (MPA) bind to the human androgen receptor with an affinity close to that of dihydrotestosterone (DHT), the body’s most potent natural androgen. NETA’s binding affinity was measured at roughly 22 nanomolar compared with about 29 nanomolar for DHT, and in gene-activation assays both NETA and MPA acted as full androgen-receptor agonists with activity comparable to DHT.³ Natural progesterone, by contrast, bound the receptor at a similar strength but did not actually switch on androgen-driven gene activity, making it a weak binder with no functional androgenic punch.

Comparative work looking across multiple progestin generations confirmed these findings: first-, second-, and third-generation progestins, including NETA and levonorgestrel, showed androgenic potency similar to DHT in transactivation assays, while also acting as estrogen-receptor-alpha agonists.⁴ For patients, this dual activity is not just academic. The androgenic side explains why NETA can worsen acne or oily skin in some users, and it is why newer “anti-androgenic” progestins like drospirenone are sometimes preferred for contraception in people prone to hormonal breakouts. Oral contraceptives containing first- or second-generation progestins like NET can trigger or worsen acne precisely because of this androgenic load.

Managing Heavy Menstrual Bleeding

Heavy menstrual bleeding, sometimes called abnormal uterine bleeding, is one of the most common reasons NETA is prescribed. Among oral progestins used for this purpose, norethisterone is the most widely chosen worldwide, given to an estimated 38% of women treated for heavy periods thanks to its relative affordability and tolerability. At a standard dose of 5 mg three times daily from day 5 to day 26 of the cycle, it can reduce blood loss by more than 80%.⁵ The mechanism is straightforward: by supplementing progesterone-like signaling, the drug stabilizes the uterine lining, prevents its erratic breakdown, and controls the volume and timing of bleeding.

NETA is also widely used to deliberately delay a period for convenience, such as during travel or an important event. In many countries, norethisterone tablets are available without a prescription for this specific purpose, typically taken for up to two weeks. Bleeding usually begins a few days after stopping. This short-term use is generally well tolerated, though bloating, breast tenderness, and mood shifts are reported by a minority of users.

Endometriosis Treatment

Endometriosis management is an area where NETA has accumulated a substantial track record. The drug works here by thinning the endometrial-like tissue that grows outside the uterus and suppressing the hormonal cycling that fuels pain. In one study following women with rectovaginal endometriosis over five years of continuous NETA use, chronic pelvic pain and deep pain during intercourse both dropped significantly compared with baseline. Imaging at five years showed that about 56% of patients had a partial radiological response, while roughly a third had stable disease.⁶

Shorter-term data paint a similar picture. In a group of 52 women with symptomatic endometriosis, overall pain relief was achieved in about 94% of patients, with dysmenorrhea specifically resolving in over 92%.⁷ For ovarian endometriomas specifically, six months of norethisterone shrank the cysts and fully relieved menstrual pain in all patients studied.⁸ These results are encouraging, but the drug is generally considered a management tool rather than a cure. Pain tends to return once treatment stops, which is why many patients stay on it long-term.

Compared with GnRH agonists, which are sometimes called the “gold standard” for endometriosis suppression, NETA has the advantage of being far cheaper, orally administered, and better tolerated for extended use. GnRH agonists induce a temporary menopause-like state with hot flashes and bone-density loss, limiting their use to about six months at a stretch without add-back therapy. NETA avoids those particular problems, though it brings its own set of side effects including breakthrough bleeding, especially in the first few months.

Role in Menopausal Hormone Therapy

For postmenopausal women who still have a uterus, taking estrogen alone to manage hot flashes, sleep disruption, and vaginal dryness raises the risk of endometrial overgrowth and, eventually, endometrial cancer. Adding a progestogen counteracts that risk by keeping the uterine lining thin. NETA is one of the most widely used progestins for this purpose, available both as an oral tablet combined with estradiol and as a transdermal patch.

The endometrial protection is well documented. In a large trial, unopposed estradiol at 1 mg per day caused endometrial hyperplasia in about 15% of women over 12 months. When NETA was added in continuous-combined regimens, that rate dropped below 1% regardless of the NETA dose tested.⁹ A two-year study of transdermal estradiol combined with NETA similarly reported zero cases of endometrial hyperplasia or cancer across the full follow-up period.¹⁰ In sequential regimens, where NETA is given for only part of the month, transdermal doses as low as 140 micrograms per day were effective at preventing hyperplasia.¹¹

One subtlety worth knowing: because NETA partially converts to ethinyl estradiol in the body, switching to a hormone therapy formulation containing NETA adds a small additional estrogenic stimulus beyond whatever estradiol dose is prescribed. Clinicians generally account for this, but patients sometimes do not realize that their progestogen component is quietly doing double duty as a weak estrogen.

Blood Clot Risk Compared with Other Progestins

Venous thromboembolism, the umbrella term for deep-vein clots and pulmonary embolism, is a well-known concern with combined hormonal contraceptives. Different progestins carry different levels of risk, and NETA has historically been grouped with levonorgestrel as a “lower-risk” progestin. A pooled analysis drawing on four large prospective cohort studies confirmed that picture: among women using combined pills containing 30 micrograms or less of ethinyl estradiol, those taking NET or NETA had a clot risk statistically indistinguishable from levonorgestrel users, with an adjusted hazard ratio of 0.73 and the confidence interval crossing 1.0.¹² The analysis was able to rule out a 1.5-fold increase in risk for NET/NETA relative to levonorgestrel, which is reassuring for prescribers choosing between these options.

Keep in mind that progestin-only formulations, including NETA used alone for endometriosis or period management, carry a substantially lower clot risk than any combined pill, because it is the estrogen component that drives most of the thrombotic risk. When NETA is prescribed as a standalone tablet for endometriosis or heavy bleeding, the absolute clot risk is much closer to that of the general population than it would be in a combined contraceptive context.

Metabolic and Cardiovascular Effects

Because NETA ends up activating androgen, estrogen, and progesterone pathways simultaneously, its metabolic fingerprint is unusually complex. A meta-analysis of randomized trials in postmenopausal women found that transdermal estradiol plus NETA significantly lowered LDL cholesterol by about 13 mg/dL and total cholesterol by roughly the same amount, while also reducing fibrinogen and factor VII, two proteins involved in blood clotting.¹³ The combination did not significantly affect HDL cholesterol, triglycerides, fasting blood sugar, insulin, body weight, or waist-to-hip ratio.

Earlier work had raised a more nuanced picture depending on the estrogen paired with NETA. When NETA was added to ethinyl estradiol, it reversed the estrogen-driven rise in HDL (the “good” cholesterol) and raised LDL, and the combination impaired glucose tolerance. But when paired with estradiol valerate instead of ethinyl estradiol, NETA still shifted lipids in an unfavorable direction but did not worsen glucose handling.¹⁴ The takeaway for patients is that the metabolic impact of NETA is not fixed; it depends heavily on the estrogen it is combined with and the route of delivery. Transdermal combinations appear more metabolically neutral than oral ones containing ethinyl estradiol.

Breast Cancer and Long-Term Hormonal Safety

Any discussion of progestins used long-term has to address breast cancer risk, and the evidence here is not entirely reassuring. Large observational analyses consistently show that estrogen-progestogen combinations carry a higher breast cancer risk than estrogen alone. A recent update synthesizing data across many studies found that five to nine years of combined estrogen-progestogen therapy was associated with roughly double the odds of breast cancer, compared with about a 60% increase for estrogen-only therapy over the same timeframe.¹⁵ These numbers apply to estrogen-progestogen therapy as a category; the data have not yet separated NETA cleanly from other progestins in head-to-head comparisons of breast cancer risk. Whether NETA’s conversion to ethinyl estradiol adds a specific additional layer of risk compared with progestins that lack estrogenic metabolites remains an open question that the existing data cannot fully answer.

A separate concern that has received attention in recent years is the link between progestins and meningioma, a usually benign brain tumor. A large study examining various progestogens found that combined oral contraceptives containing norethisterone had an odds ratio for meningioma of 1.38, but with a confidence interval spanning 0.77 to 2.47, meaning the finding was not statistically significant.¹⁶ Several other progestins, including levonorgestrel and gestodene, showed slightly stronger associations. The progestins most clearly linked to meningioma risk are high-dose cyproterone acetate and chlormadinone acetate, neither of which is chemically related to NETA. For norethisterone users, the current evidence does not point to a meaningful meningioma signal, though surveillance continues.

Mood, Libido, and Neuropsychiatric Effects

Progestogens have a complicated relationship with mood and sexual desire, and NETA is no exception. In a study comparing estradiol alone with estradiol combined with NETA for long-term menopausal hormone therapy, women in the combined groups reported less improvement in sexual desire and emotional well-being than those on estradiol alone.¹⁷ Notably, there was no increase in negative side effects overall; it was more that the progestogen blunted the mood and libido boost that estradiol provided on its own. This dampening effect is reported across several progestins, not just NETA, and it is one reason some clinicians prefer the lowest effective progestogen dose or opt for local delivery methods like a progestogen-releasing intrauterine device, which limits systemic progestogen exposure.

For younger users taking NETA for endometriosis or period problems, anecdotal reports of low mood and irritability are common, though large controlled trials specifically isolating NETA’s psychiatric effects are sparse. If mood worsens after starting the drug, it is worth discussing with a prescriber rather than assuming it is unrelated. Switching progestin type, adjusting the dose, or changing the route of administration can sometimes help.

Drug Interactions That Actually Matter

NETA is metabolized through the liver enzyme CYP3A, which means it is vulnerable to drugs that rev up or slow down that enzyme. The interaction most worth knowing about involves rifampicin, an antibiotic used mainly for tuberculosis. Strong CYP3A induction by rifampicin reduced norethindrone exposure by 57% to 90%, enough to potentially render the drug ineffective as a contraceptive or as a treatment for bleeding and endometriosis. Even weak CYP3A induction led to meaningful though smaller decreases of 15% to 37%.¹⁸ Other strong CYP3A inducers, including certain anti-seizure medications like carbamazepine and phenytoin, as well as the herbal supplement St. John’s wort, carry a similar theoretical risk. If you are taking any of these alongside NETA, your prescriber should be aware so the dose or method can be adjusted.

Use in Transgender and Gender-Diverse Adolescents

An emerging application for NETA is menstrual suppression in transgender males and gender-diverse young people for whom menstruation causes significant distress. In a study of 101 adolescents seeking menstrual management, 90% chose either oral norethindrone acetate or a levonorgestrel intrauterine device. Both methods performed similarly: almost all users reported improved bleeding, with amenorrhea rates reaching 97% for NETA users and 89% for IUD users by the second follow-up. Pain, menstrually related mood disruption, and menstrually related dysphoria all improved in the majority of patients, with no significant differences in side effects or satisfaction between the two approaches.¹⁹

For those also starting testosterone therapy, adding NETA can accelerate the time to menstrual cessation. In one cohort, patients who began NETA alongside testosterone waited a median of about 188 days for menses to stop, while those who added NETA after testosterone was already established reached cessation faster, at a median of 56 days. Patients using NETA alone without testosterone reached cessation in roughly 78 days, comparable to depot leuprolide, a far more expensive injectable option.²⁰ NETA’s oral route, low cost, and generally mild side-effect profile make it an attractive first-line choice for menstrual suppression in this population, though individual responses vary and some patients eventually switch to an IUD or other method for convenience.

Skin and Hair Effects

Given the androgenic receptor activity described earlier, it should not be surprising that NETA can affect the skin. Oral contraceptives containing first- or second-generation progestins like norethisterone can trigger or exacerbate acne in susceptible individuals, despite the fact that most combined pills improve acne overall thanks to their estrogen component raising sex-hormone-binding globulin and reducing free testosterone. The androgenic push from NETA can partially counteract that benefit. For someone already prone to hormonal acne, a pill containing a newer, anti-androgenic progestin like drospirenone or cyproterone acetate tends to be a better fit.

Hirsutism, or excess hair growth in androgen-sensitive areas, is another potential side effect, though it is less commonly reported at the doses used for period management or endometriosis than at the higher doses sometimes used in menopausal therapy. If unwanted hair growth does develop, it is usually reversible after stopping the medication, though it may take several months for follicles to return to their baseline behavior.

Oral Versus Transdermal Delivery

The route by which NETA reaches the body matters more than many patients realize. Oral tablets pass through the liver before entering the general circulation, a process called first-pass metabolism. This hepatic exposure amplifies certain effects, including changes to clotting factors and lipids, and it is where the conversion to ethinyl estradiol primarily occurs. Transdermal patches bypass the liver on first pass, delivering NETA directly into the bloodstream through the skin. The result is a cleaner metabolic profile: lower impact on clotting proteins, more favorable lipid shifts, and likely less of the ethinyl estradiol conversion that complicates the oral form’s risk picture.

In menopausal hormone therapy, the transdermal estradiol-NETA combination has shown reductions in LDL cholesterol and clotting factors without the unfavorable HDL and triglyceride changes seen with some oral combinations.²¹ For women at higher cardiovascular risk or with a history of clotting issues who still need progestogenic endometrial protection, transdermal delivery is often the preferred route. The trade-off is convenience: patches need to be changed regularly, can cause skin irritation, and occasionally detach during physical activity or hot weather.